<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34233060</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Early diagnosis of amyotrophic lateral sclerosis by threshold tracking and conventional transcranial magnetic stimulation.</ArticleTitle><Pagination><StartPage>3030</StartPage><EndPage>3039</EndPage><MedlinePgn>3030-3039</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15010</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Short-interval intracortical inhibition by threshold tracking (T-SICI) has been proposed as a diagnostic tool for amyotrophic lateral sclerosis (ALS) but has not been compared directly with conventional amplitude measurements (A-SICI). This study compared A-SICI and T-SICI for sensitivity and clinical usefulness as biomarkers for ALS.</AbstractText><AbstractText Label="METHODS">In all, 104 consecutive patients referred with suspicion of ALS were prospectively included and were subsequently divided into 62 patients with motor neuron disease (MND) and 42 patient controls (ALS mimics) by clinical follow-up. T-SICI and A-SICI recorded in the first dorsal interosseus muscle (index test) were compared with recordings from 53 age-matched healthy controls. The reference standard was the Awaji criteria. Clinical scorings, conventional nerve conduction studies and electromyography were also performed on the patients.</AbstractText><AbstractText Label="RESULTS">Motor neuron disease patients had significantly reduced T-SICI and A-SICI compared with the healthy and patient control groups, which were similar. Sensitivity and specificity for discriminating MND patients from patient controls were high (areas under the receiver operating characteristic curves 0.762 and 0.810 for T-SICI and A-SICI respectively at 1-3.5&#xa0;ms). Paradoxically, T-SICI was most reduced in MND patients with the fewest upper motor neuron (UMN) signs (Spearman &#x3c1;&#xa0;=&#xa0;0.565, p&#xa0;=&#xa0;4.3&#xa0;&#xd7;&#xa0;10<sup>-6</sup> ).</AbstractText><AbstractText Label="CONCLUSIONS">Amplitude-based measure of cortical inhibition and T-SICI are both sensitive measures for the detection of cortical involvement in MND patients and may help early diagnosis of ALS, with T-SICI most abnormal before UMN signs have developed. The gradation in T-SICI from pathological facilitation in patients with minimal UMN signs to inhibition in those with the most UMN signs may be due to progressive degeneration of the subset of UMNs experiencing facilitation.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tankisi</LastName><ForeName>Hatice</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8495-9769</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Christina S-Z</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howells</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cengiz</LastName><ForeName>B&#xfc;lent</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1688-9516</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Gazi University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samusyte</LastName><ForeName>Gintaute</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koltzenburg</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, National Hospital for Neurology and Neurosurgery, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blicher</LastName><ForeName>Jakob U</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Functionally Integrated Neuroscience, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Anette T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugdahl</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuglsang-Frederiksen</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Univeridade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universit&#xe1;rio de Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bostock</LastName><ForeName>Hugh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K015222/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019054" MajorTopicYN="N">Evoked Potentials, Motor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">conventional TMS</Keyword><Keyword MajorTopicYN="N">short-interval intracortical inhibition</Keyword><Keyword MajorTopicYN="N">threshold tracking TMS</Keyword><Keyword MajorTopicYN="N">transcranial magnetic stimulation</Keyword></KeywordList><CoiStatement>H. Bostock and J. Howells receive from UCL a share of the royalties for sales of their QtracW software used in this study. Other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>17</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34233060</ArticleId><ArticleId IdType="pmc">PMC9291110</ArticleId><ArticleId IdType="doi">10.1111/ene.15010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Carrero JJ, Zagai U, et al. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(11):2125&#x2010;2133.</Citation><ArticleIdList><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(6):1010&#x2010;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">32097525</ArticleId></ArticleIdList></Reference><Reference><Citation>Petimar J, O'Reilly &#xc9;, Adami HO, et al. Coffee, tea, and caffeine intake and amyotrophic lateral sclerosis mortality in a pooled analysis of eight prospective cohort studies. Eur J Neurol. 2019;26(3):468&#x2010;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365186</ArticleId><ArticleId IdType="pubmed">30326172</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(2):251&#x2010;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437330</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497&#x2010;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918&#x2010;1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: a six&#x2010;month longitudinal study. Muscle Nerve. 2010;41:208&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">19697379</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015;14:478&#x2010;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lazzaro V, Oliviero A, Profice P, et al. The diagnostic value of motor evoked potentials. Clin Neurophysiol. 1999;110(7):1297&#x2010;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">10423196</ArticleId></ArticleIdList></Reference><Reference><Citation>Truffert A, R&#xf6;sler KM, Magistris MR. Amyotrophic lateral sclerosis versus cervical spondylotic myelopathy: a study using transcranial magnetic stimulation with recordings from the trapezius and limb muscles. Clin Neurophysiol. 2000;111(6):1031&#x2010;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">10825710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol. 1993;471:501&#x2010;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1143973</ArticleId><ArticleId IdType="pubmed">8120818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, Winter M, Reimers CD, et al. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology. 1997;49:1292&#x2010;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9371911</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher RJ, Nakamura Y, Bestmann S, et al. Two phases of intracortical inhibition revealed by transcranial magnetic threshold tracking. Exp Brain Res. 2002;143:240. e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11880900</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006;129:2436&#x2010;2446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16835248</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. Handb Clin Neurol. 2013;116:561&#x2010;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">24112924</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, van den Bos M, Menon P, et al. Utility of threshold tracking transcranial magnetic stimulation in ALS. Clin Neurophysiol Practice. 2018;3:164&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6275211</ArticleId><ArticleId IdType="pubmed">30560220</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Transcranial magnetic stimulation for the assessment of neurodegenerative disease. Neurotherapeutics. 2017;14:91e106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233629</ArticleId><ArticleId IdType="pubmed">27830492</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M. Electrodiagnosis of amyotrophic lateral sclerosis: a review of existing guidelines. J Clin Neurophysiol. 2020;37:294&#x2010;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">33151660</ArticleId></ArticleIdList></Reference><Reference><Citation>Tankisi H, Cengiz B, Howells J, et al. Short&#x2010;interval intracortical inhibition as a function of inter&#x2010;stimulus interval: three methods compared. Brain Stim. 2021;14:22&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">33166726</ArticleId></ArticleIdList></Reference><Reference><Citation>Samusyte G, Bostock H, Rothwell J, Koltzenburg M. Short&#x2010;interval intracortical inhibition: comparison between conventional and threshold tracking techniques. Brain Stim. 2018;11:806&#x2010;817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6028741</ArticleId><ArticleId IdType="pubmed">29573989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623764</ArticleId><ArticleId IdType="pubmed">26511519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Howells J, Matamala JM, et al. Cortical inexcitability defines an adverse clinical profile in amyotrophic lateral sclerosis. Eur J Neurol. 2021;28(1):90&#x2010;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820947</ArticleId><ArticleId IdType="pubmed">32902860</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JH, Wang S, Melhem ER, et al. Linear associations between clinically assessed upper motor neuron disease and diffusion tensor imaging metrics in amyotrophic lateral sclerosis. PLoS One. 2014;9:e105753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140827</ArticleId><ArticleId IdType="pubmed">25144708</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Edmundson C, Dahodwala N, Elman L. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve. 2020;61:508&#x2010;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">31743477</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore SR, Gresham LS, Bromberg MB, et al. A self report measure of affective lability. J Neurol Neurosurg Psychiatry. 1997;63:89&#x2010;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169647</ArticleId><ArticleId IdType="pubmed">9221973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohannon R, Smith M. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206&#x2010;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">3809245</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13&#x2013;.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tankisi H, Pugdahl K, Johnsen B, Fuglsang&#x2010;Frederiksen A. Correlations of nerve conduction measures in axonal and demyelinating polyneuropathies. Clin Neurophysiol. 2007;118:2383&#x2010;2392.</Citation><ArticleIdList><ArticleId IdType="pubmed">17900975</ArticleId></ArticleIdList></Reference><Reference><Citation>Tankisi H, Pugdahl K, Beniczky S, et al. Evidence&#x2010;based recommendations for examination and diagnostic strategies of polyneuropathy electrodiagnosis. Clin Neurophysiol Pract. 2019;4:214&#x2010;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921232</ArticleId><ArticleId IdType="pubmed">31886447</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirota Y, Ohminami S, Tsutsumi R, et al. Increased facilitation of the primary cortex in de novo Parkinson&#x2019;s disease. Parkinsonism Rel Disord. 2019;66:125&#x2010;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">31327628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540&#x2010;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011;122:1860&#x2010;1866.</Citation><ArticleIdList><ArticleId IdType="pubmed">21382747</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Bos MAJ, Higashihara M, Geevasinga N, et al. Pathophysiological associations of transcallosal dysfunction in ALS. Eur J Neurol. 2021;28(4):1172&#x2010;1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">33220162</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al&#x2010;Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975&#x2010;1978.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>